Abstracts tagged "rheumatoid arthritis (RA) and therapy"

Abstract Number: 569 • 2018 ACR/ARHP Annual Meeting
Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry
Joel Kremer^1,2, J. Lynn Palmer³, George W. Reed⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶, Jeffrey Greenberg¹ and Jeffrey R. Curtis⁷, ¹Corrona LLC, Waltham, MA, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Corrona Research Foundation, Albany, NY, ⁴UMass Medical School, Worcester, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The combination of methotrexate (MTX), hydroxychloroquine (HCQ) and sulfasalazine (SSZ) has been called Triple Therapy (Triple) and has been compared with a combination of…
Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Christof Specker¹, Annette Alberding², Martin Aringer³, Gerd R. Burmester⁴, Jan-Paul Flacke⁵, Michael Hofmann⁶, Peter Kaestner⁷, Herbert Kellner⁸, Frank Moosig⁹, Maren Sieburg¹⁰, Hans-Peter Tony¹¹ and Gerhard Fliedner¹², ¹Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, ²Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, ³Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁶Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ⁷Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ⁸Ambulantes Rheumazentrum, Erfurt, Germany, ⁹Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, ¹⁰Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ¹¹Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, ¹²Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
Abstract Number: 2432 • 2018 ACR/ARHP Annual Meeting
Peripartum Issues in the Inflammatory Arthritis (IA) Patient: A Survey of the Rapport (Rheumatoid Arthritis Pharmacovigilence Program and Outcomes Research in New Therapies) Registry
Tharindri Dissanayake¹, Stephanie Keeling² and Walter P. Maksymowych³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, University of Alberta, Edmonton, AB, Canada, ³CaRE Arthritis, Edmonton, AB, Canada
Background/Purpose: Multiple issues surround the peripartum period for IA patients including medication use, risk of disease flare and potential impact on neonatal outcomes. We aimed…
Abstract Number: 2528 • 2018 ACR/ARHP Annual Meeting
A Multicenter Study Assessing the Efficacy and Safety of Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: Preliminary Interim Data from the Open-Label Treatment Period
Roy Fleischmann¹, Daniel E. Furst², Richard Brasington³, Erin Connolly-Strong⁴, Jingyu Liu⁴ and Matthew E. Barton⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Washington University School of Medicine, St. Louis, MO, ⁴Mallinckrodt ARD, Inc., Bedminster, NJ
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder associated with chronic inflammation and commonly treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. Repository corticotropin injection…
Abstract Number: 2536 • 2018 ACR/ARHP Annual Meeting
Vagus Nerve Stimulation in Patients with Rheumatoid Arthritis: 24 Month Safety and Efficacy
Frieda A. Koopman¹, Anne Musters², Marieke M.J. Backer², Danielle Gerlag², Sanda Miljko³, Simeon Grazio⁴, Sekib Sokolovic⁵, Yaakov Levine⁶, David Chernoff⁶, Niek de Vries⁷ and Paul-Peter Tak², ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinical Hospital, Mostar, Bosnia, ⁴Vinogradsira 29, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ⁵Rheumatology, Sarajevo University Clinical Center, Sarajevo, BA, ⁶SetPoint Medical, Inc., Valencia, CA, ⁷Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: RA is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Modulating innate neuro-immune reflex pathways by stimulation of the vagus…
Abstract Number: 529 • 2017 ACR/ARHP Annual Meeting
Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience
Edurne Guerrero Basterretxea¹, Maria Luz Garcia Vivar¹, Itziar Calvo Zorrilla¹, Oihane Ibarguengoitia², Eva Galíndez Agirregoikoa², Juan Maria Blanco Madrigal³, Esther Ruíz Lucea¹, Ignacio Torre Salaberri¹, Olaia Begoña Fernandez Berrizbeitia², Clara Eugenia Perez¹, Ana Rosa Intxaurbe Pellejero², Natalia Rivera-García⁴ and Iñigo Gorostiza Hormaetxe⁵, ¹RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, BILBAO, Spain, ³Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ⁴RESEARCH, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ⁵RESEARCH, Research Department. Basurto University Hospital, BILBAO, Spain
Background/Purpose: Use of biological therapy (BT) has dramatically improved Rheumatoid Arthritis (RA) management and outcomes for the last decade. Classic extraarticular manifestations are now uncommon,…
Abstract Number: 2483 • 2017 ACR/ARHP Annual Meeting
Cycling Versus Swapping in Patients with Rheumatoid Arthritis with an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor: A Systematic Review and Meta-Analysis of Observational Studies
Maria A. Lopez-Olivo, Aliza Matusevich and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: In patients with rheumatoid arthritis (RA) who do not respond or lose response to a tumor necrosis factor inhibitor (TNFi), opinions are divided on…
Abstract Number: 1418 • 2016 ACR/ARHP Annual Meeting
Rheumatologist: If You Fell Ill with Seropositive Active Rheumatoid Arthritis Yourself, What to Do!
Kalle Aaltonen¹, Elena Nikiphorou^2,3, Nasim A. Khan⁴ and Tuulikki Sokka⁵, ¹Helsinki University, Helsinki, Finland, ²Whittington Hospital, London, United Kingdom, ³Jyväskylä Central Hospital, Jyväskylä, Finland, ⁴Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, ⁵Jyvaskyla Central Hospital, Jyväskylä, Finland
Background/Purpose: International and national bodies have given evidence-based recommendations for rheumatoid arthritis (RA) treatment. We assessed the general uptake of these recommendations by asking rheumatologists…
Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting
Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
Jon T. Einarsson¹, Minna Willim¹, Sofia Ernestam², Tore Saxne¹, Pierre Geborek¹ and Meliha C. Kapetanovic¹, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…
Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting
Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Susan J. Bartlett^1,2, Orit Schieir³, Kathleen Andersen⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet E. Pope⁹, J Carter Thorne¹⁰, Diane Tin¹¹, Vivian P. Bykerk¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁶1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
Abstract Number: 1302 • 2016 ACR/ARHP Annual Meeting
Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Dr. Philipp Sewerin¹, PD Dr. Stefan Vordenbäumen¹, Annika Hoyer², Ralph Brinks¹, Dr. Christian Buchbender³, Dr. Christoph Schleich⁴, Sabine Kamp¹, Prof. Dr. Gerald Antoch³, Prof. Dr. Matthias Schneider¹ and Prof. Dr. Benedikt Ostendorf¹, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine University, Düsseldorf, Germany, ²Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, ³Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Dep. for diagnostic and interventional Radiology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: disease activity score in 28 joints; Methods: Data-sets of 80 RA patients from the REMISSION-plus study cohort who fulfilled the following criteria were retrospectively…
Abstract Number: 1306 • 2016 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy
Paolo Pace¹, Arthur Lau², Jonathan D. Adachi³, Matthew A. Jessome⁴, George Ioannidis² and Minta Patel⁵, ¹Rheumatology, McMaster Unversity, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ⁵Cambridge Memorial Hospital, Cambridge, ON, Canada
Background/Purpose: Magnetic resonance imaging ( MRI ) in rheumatoid arthritis ( RA ) has been shown to be more sensitive than clinical and radiological parameters…
Abstract Number: 28 • 2015 ACR/ARHP Annual Meeting
The Decrease over Time of Orthopaedic Surgery in Patients with Rheumatoid Arthritis Is Mainly Due to Reduced Rates Among Those with Rheumatoid Factor Positive Disease – Results from a Well Defined Area
Korosh Hekmat^1,2, Lennart T.H. Jacobsson³, Jan-Åke Nilsson¹, Minna Willim¹, Martin Englund^4,5, Ingemar F Petersson⁴ and Carl Turesson⁶, ¹Department of Rheumatology. Malmö University Hospital, Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Karolinska University Hospital, Department of Medicine, Unit of Rheumatology, Stockholm, Stockholm, Sweden, ³Department of Rheumatology Malmö University Hospital, Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Clinical Epidemiology Unit, Orthopedics, Dept of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose : Seropositive and seronegative rheumatoid arthritis (RA) differ in course and prognostic feature. The overall incidence of orthopaedic surgery in patients with RA has…
Abstract Number: 449 • 2015 ACR/ARHP Annual Meeting
Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
Ruediger Mueller¹, Michael Gengenbacher², Symi richter³, Jean Dudler⁴, Burkhard Moeller⁵ and Johannes von Kempis⁶, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Bethesdaspital, Basel, Switzerland, ³Bethsdaspital, Basel, Switzerland, ⁴Kantonsspital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Holiday seasons can present a major problem to RA patients treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore an evaluation of the…
Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].